Abkyu and Artemia Therapeutics Announce Strategic VHH Discovery Partnership

WATERTOWN, Mass., May 21, 2026 — Abkyu, Inc., a biotechnology company specializing in single-domain antibody (VHH) discovery, today announced it has entered into a strategic discovery partnership with Artemia Therapeutics, Inc., a biotechnology company developing multi-specific T-cell engagers for autoimmune diseases and oncology, to discover and develop novel VHH candidates for their therapeutic programs. The […]